

9 April 2014

Resonance Announces Placement and Entitlement Offer to Raise up to \$5.1 million

Resonance Health Limited (**ASX: RHT**) (**Resonance** or **the Company**) is pleased to announce its intention to raise up to \$5.1 million (before costs) via a placement (**Placement**) and non-renounceable entitlement offer (**Entitlement Offer**) (together **the Offer**).

The issue price for shares offered under both the Placement and Entitlement Offer (**New Shares**) will be A\$0.05 per New Share (**Issue Price**). This issue price represents a discount of 20% to Resonance's last closing price of \$0.063 on Monday 7 April 2014.

New Shares issued under the Offer will rank pari passu with existing ordinary shares on issue and an application will be made for their quotation.

The proceeds of the Offer will be used to:

- Further the development of the Company's MRI based intellectual property including HepaFat-Scan[®], a Liver Fibrosis test and other products; and
- General working capital (including costs of the Offer).

Placement

The Placement will comprise an offer of 10 million shares (**the Placement Shares**) at the Issue Price to raise total proceeds of \$0.5 million before costs. The Placement will be undertaken to sophisticated investors without shareholder approval out of the Company's placement capacity pursuant to Listing Rule 7.1. The Placement Shares will be entitled to participate in the Entitlement Offer.

Entitlement Offer

The Entitlement Offer will give existing eligible Resonance shareholders the opportunity to subscribe for one (1) New Share for every four (4) existing Resonance shares held at 5.00pm (AEDT) on 30 April 2014 (**Record Date**). The Entitlement Offer will comprise the offer of approximately 92.7 million shares (**the Entitlement Offer Shares**) at the Issue Price to raise total proceeds of approximately \$4.6m before costs. The Entitlement Offer is non-renounceable which means that shareholders who do not take up their entitlement will not receive any proceeds from the sale of entitlements not taken up. The entitlements to participate in the Entitlement Offer are not transferable and cannot be traded on the ASX or any other exchange or privately traded. The Entitlement Offer has not been underwritten.

The timetable for the Entitlement Offer and Placement is as follows:

Trading Halt	8 April
Announcement of Placement and Entitlement Offer and Resumption of Trading	10 April
Settlement of Placement	15 April
Allotment & Trading of Placement shares	16 April
Lodgment of Offer Document, Appendix 3B and s708AA Cleansing Notice with ASX	17 April
Record Date for participation in Entitlement Offer	30 April
Dispatch of Entitlement Offer Document completed & Entitlement Offer Opening Date	2 May
Entitlement Offer Closing Date	23 May

This timetable is indicative only and may be subject to change. Subject to the Corporations Act and ASX Listing Rules, Resonance reserves the right to vary the dates and times in conjunction with the Entitlement Offer, including the closing date, without prior notice.

If there is a shortfall in subscriptions under the Entitlement Offer, the Company reserves the right to place the shortfall shares at their discretion within three months of the closing date of the offer.

Azure Capital Ltd has been engaged as Lead Manager in relation to the Placement and Entitlement Offer.

For further information please contact:

Resonance Health

Liza Dunne

Managing Director

T: +61 8 9286 5300

E: lizad@resonancehealth.com

Adrian Bowers

Company Secretary

T: +61 8 9286 5300

E: adrianb@resonancehealth.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration. HepaFat-Scan is FDA cleared for the measurement of liver fat and research continues into the development of new technology for the accurate assessment of liver fibrosis.